Quotient Clinical announces RapidFACT™ collaboration with Pulmatrix to develop a new bronchodilator therapy for COPD
Quotient Clinical today announced a collaboration with Pulmatrix Inc, a Massachusetts’s based biotech company, to support the development of PUR0200. The new bronchodilator therapy for the treatment of chronic obstructive pulmonary disease (COPD) and the first small molecule product to emerge from Pulmatrix’s novel inhaled iSPERSETM technology platform.
Quotient will employ its RapidFACT™ (Rapid Formulation development And Clinical Testing) service to manufacture the spray dried PUR0200 product in ‘real-time’ to support the Phase 1B clinical study in COPD patients. This capability allows within-protocol adjustment of the formulation composition in response to arising safety, pharmacokinetic and pharmacodynamic data to optimize performance. The clinical study is being performed at the Quotient Clinical site in Nottingham, England and in conjunction with Professor David Singh at the Medicines Evaluation Unit in Manchester, England.
Mark Egerton, Managing Director of Quotient Clinical, commented:
“We are delighted that Pulmatrix has chosen to utilise our RapidFACT™ service to support the development PUR0200. We have proven that RapidFACT™ can shorten timelines and reduce costs in early development, which ultimately contributes to enhancing R&D productivity. This particular study also demonstrates our ability to manufacture and supply drug product in real time to other clinical centres of excellence that specialise in specific disease indications and endpoints.”